Literature DB >> 26514357

The Clinical and Histological Spectrum of Idiopathic Inflammatory Myopathies.

Ilaria Cavazzana1, Micaela Fredi2, Carlo Selmi3, Angela Tincani2, Franco Franceschini2.   

Abstract

Idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of myositis, characterised by chronic muscle weakness, cutaneous features, different extra-muscular manifestations and circulating autoantibodies. IIMs included classical polymyositis (PM), dermatomyositis (DM) and other different types of myositis with a wide range of muscle involvement. A complete autoantibody profile and a muscle biopsy are mandatory to correctly diagnose different clinical entities and to define their different prognosis. Bohan and Peter's criteria included five items to diagnose adult onset PM and DM. The sensitivity was 74-100 %, while the specificity is low, due to a poor ability to differentiate PM from neuromuscular diseases. Other criteria included a more accurate histological definition of PM, DM or amyopathic DM, obtaining a higher specificity. Autoantibodies' association, interstitial lung disease and clinical cardiac involvement represent the main items that could define the prognosis of these patients. On the other hand, inclusion body myositis is a different myopathy characterised by a peculiar muscle mass involvement, muscle atrophy and progressive loss of function, due to complete failure to all immunosuppressive drugs used. Treatment of IIMs is based on corticosteroids (CS), which show rapid clinical response and functional improvement. Different immunosuppressant drugs are given to obtain a better control of the disease during CS tapering dose. No controlled double blind trials demonstrated the superiority of one immunesuppressant on another. The occurrence of interstitial lung involvement requires the immediate introduction of immunosuppressants in addiction to CS. Severe dysphagia seems to improve with intravenous immunoglobulins (Ig). Physical therapy could be started after the acute phase of diseases and seems to have a beneficial role in muscle strength recovery.

Entities:  

Keywords:  Dermatomyositis; Muscle biopsy; Muscle enzyme; Myositis; Myositis treatment

Mesh:

Year:  2017        PMID: 26514357     DOI: 10.1007/s12016-015-8517-4

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  95 in total

Review 1.  Polymyositis, dermatomyositis and inclusion-body myositis.

Authors:  M C Dalakas
Journal:  N Engl J Med       Date:  1991-11-21       Impact factor: 91.245

Review 2.  Incidence and prevalence of inflammatory myopathies: a systematic review.

Authors:  Alain Meyer; Nicolas Meyer; Mickael Schaeffer; Jacques-Eric Gottenberg; Bernard Geny; Jean Sibilia
Journal:  Rheumatology (Oxford)       Date:  2014-07-26       Impact factor: 7.580

3.  Myositis-specific and myositis-associated antibodies in overlap myositis in comparison to primary dermatopolymyositis: Relevance for clinical classification: retrospective study of 169 patients.

Authors:  Andrea Váncsa; Lajos Gergely; Andrea Ponyi; Gabriella Lakos; Júlia Németh; Péter Szodoray; Katalin Dankó
Journal:  Joint Bone Spine       Date:  2010-02-25       Impact factor: 4.929

Review 4.  Exercise as a therapeutic modality in patients with idiopathic inflammatory myopathies.

Authors:  Helene Alexanderson; Ingrid E Lundberg
Journal:  Curr Opin Rheumatol       Date:  2012-03       Impact factor: 5.006

5.  Isolated elevation of aldolase in the serum of myositis patients: a potential biomarker of damaged early regenerating muscle cells.

Authors:  Livia Casciola-Rosen; John C Hall; Andrew L Mammen; Lisa Christopher-Stine; Antony Rosen
Journal:  Clin Exp Rheumatol       Date:  2012-08-29       Impact factor: 4.473

6.  Interstitial lung disease associated with anti-PM/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: a similar condition?

Authors:  Jean-Christophe Lega; Vincent Cottin; Nicole Fabien; Françoise Thivolet-Béjui; Jean-François Cordier
Journal:  J Rheumatol       Date:  2010-03-15       Impact factor: 4.666

Review 7.  Review article: the gastrointestinal complications of myositis.

Authors:  E C Ebert
Journal:  Aliment Pharmacol Ther       Date:  2009-11-03       Impact factor: 8.171

Review 8.  Overlap connective tissue disease syndromes.

Authors:  Luca Iaccarino; Mariele Gatto; Silvano Bettio; Francesco Caso; Mariaelisa Rampudda; Margherita Zen; Anna Ghirardello; Leonardo Punzi; Andrea Doria
Journal:  Autoimmun Rev       Date:  2012-06-26       Impact factor: 9.754

9.  Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology.

Authors:  Maryam Fathi; Jenny Vikgren; Marianne Boijsen; Ulf Tylen; Lennart Jorfeldt; Göran Tornling; Ingrid E Lundberg
Journal:  Arthritis Rheum       Date:  2008-05-15

10.  Redefining dermatomyositis: a description of new diagnostic criteria that differentiate pure dermatomyositis from overlap myositis with dermatomyositis features.

Authors:  Yves Troyanov; Ira N Targoff; Marie-Pier Payette; Jean-Pierre Raynauld; Suzanne Chartier; Jean-Richard Goulet; Josiane Bourré-Tessier; Eric Rich; Tamara Grodzicky; Marvin J Fritzler; France Joyal; Martial Koenig; Jean-Luc Senécal
Journal:  Medicine (Baltimore)       Date:  2014-11       Impact factor: 1.889

View more
  12 in total

1.  Panniculitis as an Initial Presentation of Dermatomyositis: A Case Report.

Authors:  Anjal Bisht; Niraj Parajuli; Monasha Vaidya; Sumida Tiwari
Journal:  JNMA J Nepal Med Assoc       Date:  2020-03       Impact factor: 0.406

Review 2.  Autoimmunity in 2017.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2018-12       Impact factor: 8.667

Review 3.  Cutaneous Manifestations of Dermatomyositis: a Comprehensive Review.

Authors:  Carlo Mainetti; Benedetta Terziroli Beretta-Piccoli; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

4.  Elevated IL-4 and IFN-γ Levels in Muscle Tissue of Patients with Dermatomyositis.

Authors:  Murat Giriş; Hacer Durmuş; Berrak Yetimler; Hatice Taşli; Yeşim Parman; Erdem Tüzün
Journal:  In Vivo       Date:  2017 Jul-Aug       Impact factor: 2.155

5.  The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies.

Authors:  Shanshan Li; Yongpeng Ge; Hanbo Yang; Tao Wang; Xiaoxiao Zheng; Qinglin Peng; Xin Lu; Guochun Wang
Journal:  Clin Rheumatol       Date:  2019-03-12       Impact factor: 2.980

6.  Anterior segment parameters associated with extramuscular manifestations in polymyositis and dermatomyositis.

Authors:  Zoltan Griger; Katalin Danko; Gabor Nemeth; Ziad Hassan; Zsuzsa Aszalos; Katalin Szabo; Levente Bodoki; Rudolf Gesztelyi; Judit Zsuga; Peter Szodoray; Adam Kemeny-Beke
Journal:  Int J Ophthalmol       Date:  2020-09-18       Impact factor: 1.779

7.  Nailfold videocapillaroscopy and serum VEGF levels in scleroderma are associated with internal organ involvement.

Authors:  Maria De Santis; Angela Ceribelli; Francesca Cavaciocchi; Chiara Crotti; Marco Massarotti; Laura Belloli; Bianca Marasini; Natasa Isailovic; Elena Generali; Carlo Selmi
Journal:  Auto Immun Highlights       Date:  2016-02-15

8.  Clinical significance of myositis-specific autoantibody profiles in Japanese patients with polymyositis/dermatomyositis.

Authors:  Jumpei Temmoku; Shuzo Sato; Yuya Fujita; Tomoyuki Asano; Eiji Suzuki; Takashi Kanno; Makiko Yashiro Furuya; Naoki Matsuoka; Hiroko Kobayashi; Hiroshi Watanabe; Tomohiro Koga; Toshimasa Shimizu; Atsushi Kawakami; Kiyoshi Migita
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

9.  ALDOA protects cardiomyocytes against H/R-induced apoptosis and oxidative stress by regulating the VEGF/Notch 1/Jagged 1 pathway.

Authors:  Gaiying Luo; Rui Wang; Hui Zhou; Xiaoling Liu
Journal:  Mol Cell Biochem       Date:  2020-10-21       Impact factor: 3.396

10.  Ultra-efficient sequencing of T Cell receptor repertoires reveals shared responses in muscle from patients with Myositis.

Authors:  Janelle M Montagne; Xuwen Alice Zheng; Iago Pinal-Fernandez; Jose C Milisenda; Lisa Christopher-Stine; Thomas E Lloyd; Andrew L Mammen; H Benjamin Larman
Journal:  EBioMedicine       Date:  2020-09-03       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.